BRPI0504199B8 - composições farmacêuticas baseadas em lopap e usos das ditas composições - Google Patents

composições farmacêuticas baseadas em lopap e usos das ditas composições

Info

Publication number
BRPI0504199B8
BRPI0504199B8 BRPI0504199A BRPI0504199A BRPI0504199B8 BR PI0504199 B8 BRPI0504199 B8 BR PI0504199B8 BR PI0504199 A BRPI0504199 A BR PI0504199A BR PI0504199 A BRPI0504199 A BR PI0504199A BR PI0504199 B8 BRPI0504199 B8 BR PI0504199B8
Authority
BR
Brazil
Prior art keywords
lopap
compositions
relates
pharmaceutical compositions
compositions based
Prior art date
Application number
BRPI0504199A
Other languages
English (en)
Inventor
Marisa Chudzinski-Tavassi Ana
Valença Reis Cleyson
Augusto Maria Durvanei
Falci Márcio
Original Assignee
Ana Marisa Chudzinski Tavassi
Biolab Sanus Farmaceutica Ltda
Fund De Amparo A Pesquisa Da Estado De Sao Paulo Fapesp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ana Marisa Chudzinski Tavassi, Biolab Sanus Farmaceutica Ltda, Fund De Amparo A Pesquisa Da Estado De Sao Paulo Fapesp filed Critical Ana Marisa Chudzinski Tavassi
Priority to BRPI0504199A priority Critical patent/BRPI0504199B8/pt
Priority to EP06775034.9A priority patent/EP1937292B1/en
Priority to JP2008529426A priority patent/JP5762670B2/ja
Priority to DK06775034.9T priority patent/DK1937292T3/en
Priority to PCT/BR2006/000180 priority patent/WO2007028223A1/en
Priority to CA2621482A priority patent/CA2621482C/en
Priority to US12/066,192 priority patent/US8673840B2/en
Priority to CN200680040955.3A priority patent/CN101365472B/zh
Priority to AU2006289678A priority patent/AU2006289678B2/en
Publication of BRPI0504199A publication Critical patent/BRPI0504199A/pt
Publication of BRPI0504199B1 publication Critical patent/BRPI0504199B1/pt
Publication of BRPI0504199B8 publication Critical patent/BRPI0504199B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Birds (AREA)
  • Communicable Diseases (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)

Abstract

composições farmacêuticas baseadas em lopap e usos das ditas composições a invenção se refere a composições farmacêuticas compreendendo: (a) uma quantidade profilática ou terapeuticamente eficaz de pelo menos um polipeptídeo substancialmente idêntico ao lopap (uma lipocalina com atividade de protease ativadora de protrombina), incluindo a forma recombinante, e (b) um veículo farmaceuticamente aceitável. a invenção também se refere a composições cosméticas baseadas em lopap, incluindo a forma recombinante, a invenção se relaciona, em especial, aos usos das ditas composições como moduladores de morte celular programada (anti-apoptótico), vasodilatores por elevação de óxido nítrico e como agentes antienvelhecimento.
BRPI0504199A 2005-09-08 2005-09-08 composições farmacêuticas baseadas em lopap e usos das ditas composições BRPI0504199B8 (pt)

Priority Applications (9)

Application Number Priority Date Filing Date Title
BRPI0504199A BRPI0504199B8 (pt) 2005-09-08 2005-09-08 composições farmacêuticas baseadas em lopap e usos das ditas composições
EP06775034.9A EP1937292B1 (en) 2005-09-08 2006-09-08 Lopap-based pharmaceutical compositions and uses thereof
JP2008529426A JP5762670B2 (ja) 2005-09-08 2006-09-08 Ｌｏｐａｐをベースとする医薬組成物およびその使用
DK06775034.9T DK1937292T3 (en) 2005-09-08 2006-09-08 Lopap-based pharmaceutical compositions and uses thereof
PCT/BR2006/000180 WO2007028223A1 (en) 2005-09-08 2006-09-08 Lopap-based pharmaceutical compositions and uses thereof
CA2621482A CA2621482C (en) 2005-09-08 2006-09-08 Lopap-based pharmaceutical compositions and uses thereof
US12/066,192 US8673840B2 (en) 2005-09-08 2006-09-08 Methods for growing tissue with Lopap-based pharmaceutical compositions
CN200680040955.3A CN101365472B (zh) 2005-09-08 2006-09-08 基于lopap的药物组合物及其应用
AU2006289678A AU2006289678B2 (en) 2005-09-08 2006-09-08 Lopap-based pharmaceutical compositions and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0504199A BRPI0504199B8 (pt) 2005-09-08 2005-09-08 composições farmacêuticas baseadas em lopap e usos das ditas composições

Publications (3)

Publication Number Publication Date
BRPI0504199A BRPI0504199A (pt) 2007-05-22
BRPI0504199B1 BRPI0504199B1 (pt) 2018-02-06
BRPI0504199B8 true BRPI0504199B8 (pt) 2021-05-25

Family

ID=37835321

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0504199A BRPI0504199B8 (pt) 2005-09-08 2005-09-08 composições farmacêuticas baseadas em lopap e usos das ditas composições

Country Status (9)

Country Link
US (1) US8673840B2 (pt)
EP (1) EP1937292B1 (pt)
JP (1) JP5762670B2 (pt)
CN (1) CN101365472B (pt)
AU (1) AU2006289678B2 (pt)
BR (1) BRPI0504199B8 (pt)
CA (1) CA2621482C (pt)
DK (1) DK1937292T3 (pt)
WO (1) WO2007028223A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2712807C (en) * 2008-01-22 2019-05-21 Janaina De Souza Ventura Peptides, compositions, and uses thereof
KR102276424B1 (ko) 2014-10-06 2021-07-12 삼성전자주식회사 로-키나제 저해제를 포함하는 세포의 노화를 감소시키기 위한 조성물 및 그의 용도
KR20160049435A (ko) 2014-10-27 2016-05-09 삼성전자주식회사 Atm 저해제를 포함하는 세포의 노화를 감소시키기 위한 조성물 및 그의 용도
JP5866053B1 (ja) * 2014-12-15 2016-02-17 株式会社ファンケル 皮膚粘弾性のマーカー及びその利用
CN114209717A (zh) * 2021-12-29 2022-03-22 贵州广济堂健康药业有限公司 鹿胶及其药物组合物和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997029792A1 (en) * 1996-02-20 1997-08-21 Cohesion Corporation Tissue sealant compositions and methods of use thereof
AU2002318356A1 (en) * 2001-06-22 2003-01-08 Incyte Genomics, Inc. Protein modification and maintenance molecules
BRPI0200269B1 (pt) * 2002-01-31 2016-07-26 Ana Marisa Chudzinski-Tavassi processo de purificação de proteínas solúveis das cerdas da l. obliqua com atividade ativadora de protrombina e uso da fração proteica
US20040084867A1 (en) * 2002-06-28 2004-05-06 Xanthus Life Sciences, Inc. Individualization of therapy with anticoagulants
BRPI0403882B8 (pt) 2004-08-24 2021-07-27 Biolab Sanus Farmaceutica Ltda sequência nucleotídica, sequência de aminoácidos, protease ativadora de protrombina recombinante (rlopap), processo para obter a mesma na forma monomérica, uso da mesma

Also Published As

Publication number Publication date
DK1937292T3 (en) 2015-10-26
AU2006289678A1 (en) 2007-03-15
BRPI0504199B1 (pt) 2018-02-06
CA2621482C (en) 2016-08-30
US8673840B2 (en) 2014-03-18
EP1937292A4 (en) 2010-02-03
WO2007028223A1 (en) 2007-03-15
JP2009507046A (ja) 2009-02-19
EP1937292A1 (en) 2008-07-02
AU2006289678B2 (en) 2012-01-19
EP1937292B1 (en) 2015-07-22
CN101365472A (zh) 2009-02-11
BRPI0504199A (pt) 2007-05-22
CA2621482A1 (en) 2007-03-15
US20090170182A1 (en) 2009-07-02
JP5762670B2 (ja) 2015-08-12
CN101365472B (zh) 2015-02-04

Similar Documents

Publication Publication Date Title
BRPI0513327A (pt) composição farmacêutica sólida ou lìquida compreendendo neurotoxina botulìnica
ECSP077197A (es) Composición terapéutica con una neurotoxina botulínica
UA116080C2 (uk) Ліофілізована композиція терапевтичного пептидного антитіла
CO2017009954A2 (es) Dominios diseñados con repeticiones de anquirina con especificidad de unión para la seroalbúmina
CL2008000899A1 (es) Compuestos derivados de 3-imidazolil-indolilo, inhibidores de la interaccion entre p53 y mdm2 y/o mdm4; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o profilaxis de enfermedades proliferativas.
BRPI1007379B8 (pt) composições farmacêuticas para o tratamento ou prevenção de infecções orais por e. coli
BRPI0515494A (pt) uso de [d-meala] 3-[etval] 4-ciclosporina para o tratamento de infecção por hepatite c e composição farmacêutica compreendendo a referida [d-meala] 3-[etval] 4-ciclosporina
AR074311A1 (es) Variantes de subtilisina aislada de bacillus, con actividad proteolitica
BRPI0504199B8 (pt) composições farmacêuticas baseadas em lopap e usos das ditas composições
EP4276180A3 (en) Clostridium histolyticum enzyme
BRPI0618488A2 (pt) proteìnas de fusão de ìntron de fator de crescimento de hepatócito
ES2572160T3 (es) Una nueva preparación farmacéutica para preeclampsia
BRPI0910461B8 (pt) hormônio de estimulação do folículo recombinante, sua composição farmacêutica, seu método de produção e seu uso
WO2011150284A3 (en) Removal of serine proteases by treatment with finely divided silicon dioxide
BR112012010252A2 (pt) variantes de glicosilação de anticorpo
BRPI0604536A (pt) terminal móvel e método para mudar o modo do mesmo
CL2008000875A1 (es) Compuestos derivados de imidazolidin-2-ona; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento y/o profilaxis de enfermedades tales como dislipidemia, diabetes, enfermedades inflamatorias, entre otras.
WO2008108830A3 (en) Immunogenic and therapeutic compositions for streptococcus pyogenes
ATE479693T1 (de) Phosphoindole als hiv-inhibitoren
BR112012013812A2 (pt) "composições para desbridamento enzimático de feridas com atividade enzimática melhorada"
CL2011003327A1 (es) Composicion farmaceutica que comprende finafloxacina y un agente antiinflamatorio; uso en el tratamiento de infecciones oftalmicas, oticas o nasales.
AR106538A1 (es) Métodos y composiciones para el tratamiento de la amiloidosis
BRPI0514600A (pt) métodos para a fabricação de um composto, para a purificação de um composto, para o tratamento de um indivìduo tendo uma condição neoplástica, tendo carcinoma de célula escamosa, e tendo carcinoma de célula basal, para a redução ou prevenção da ocorrência de uma condição neoplástica em um indivìduo, e para a redução de triglicerìdeos no soro em um indivìduo, composto, e, composição farmacêutica
WO2005123119A3 (en) Administration of neutral endopeptidase to treat inflammatory bowel disease
BRPI0821029A2 (pt) Fomulações de peg-interferon-beta

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE A DESPACHO 8.6 NA RPI 2180 DE 16/10/2012.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 38/48 , A61K 7/48 , A61P 17/00

Ipc: A61K 38/48 (2006.01), A61P 17/00 (2006.01), A61K 8

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/09/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24D Patent annual fee: restoration after fee payment